{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:46:09Z","timestamp":1789019169579,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Anti-PM\/Scl antibodies are associated with polymyositis (PM)\/systemic scleroderma (SSc) overlap syndromes and are also found in other systemic autoimmune diseases. Although anti-PM\/Scl reactivity is found in 3-11% of PM or SSc patients and in approximately 25% of PM\/SSc overlap patients, previous large studies of Japanese patients with scleroderma reported that anti-PM\/Scl are not found in Japanese patients at all. The PM\/Scl autoantigen complex comprises 11\u201316 different polypeptides; ELISA with PM1-\u03b1 peptide, which is a major epitope of the PM\/Scl complex, has frequently been used for the detection of these antibodies in recent studies. However, no ELISA kit is commercially available in Japan.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>In this study, we developed an immunoassay for measuring antibodies against recombinant PM\/Scl-100 and PM\/Scl-75 polypeptides, which are the two major targets of the complex, and we investigated their presence in 600 Japanese patients with various systemic autoimmune conditions. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts were also applied to ELISA-positive sera.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>In ELISA, 11 patients were positive for anti-PM\/Scl-100 antibodies and 7 of these 11 patients were also positive for anti-PM\/Scl-75 antibodies. Immunoprecipitation analysis using the recombinants in addition to traditional radiolabeled cell extracts confirmed that 9 out of these 11 patients immunoprecipitated the typical sets of PM\/Scl proteins. In total, 4\/16 (25%) undifferentiated connective tissue disease (UCTD) patients, 3\/126 (2.4%) dermatomyositis patients, 1\/223 (0.4%) SSc patients, 1\/88 (1.1%) Sj\u00f6gren\u2019s syndrome patients, 0\/123 patients with systemic lupus erythematosus, 0\/17 patients with overlap syndrome and 0\/7 patients with PM were judged to be positive for anti-PM\/Scl antibodies.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>This is the first report of Japanese autoimmune patients with anti-PM\/Scl antibodies. In Japanese patients, anti-PM\/Scl antibodies are only very rarely found, and they are not always specific for dermatomyositis (DM) or SSc; they are also present in various autoimmune conditions with the highest prevalence being in UCTD. All anti-PM\/Scl-positive DM cases are complicated with interstitial lung disease and\/or cancer, while no life-threatening involvement was found in other anti-PM\/Scl-positive cases. Further studies on larger cohorts are necessary to define the clinical significance of anti-PM\/Scl antibodies in autoimmune diseases.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0573-x","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T19:30:07Z","timestamp":1425929407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma"],"prefix":"10.1186","volume":"17","author":[{"given":"Yoshinao","family":"Muro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumitsu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyo","family":"Mimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,11]]},"reference":[{"key":"573_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0065-2776(08)60641-0","volume":"44","author":"EM Tan","year":"1989","unstructured":"Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93\u2013151.","journal-title":"Adv Immunol."},{"key":"573_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08916930400024612","volume":"38","author":"Y Muro","year":"2005","unstructured":"Muro Y. Antinuclear antibodies. Autoimmunity. 2005;38:3\u20139.","journal-title":"Autoimmunity."},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/s10165-009-0155-3","volume":"19","author":"M Satoh","year":"2009","unstructured":"Satoh M, Vazquez-Del Mercardo M, Chan EKL. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol. 2009;19:219\u201328.","journal-title":"Mod Rheumatol."},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s10067-011-1751-0","volume":"30","author":"ME Krzyszczak","year":"2011","unstructured":"Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EK, Bubb MR, et al. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol. 2011;30:1333\u20139.","journal-title":"Clin Rheumatol."},{"key":"573_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3899\/jrheum.090677","volume":"37","author":"O Meyer","year":"2010","unstructured":"Meyer O, De Chaisemartin L, Nicaise-Roland P, Cabane J, Tubach F, Dieude P, et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol. 2010;37:125\u201330.","journal-title":"J Rheumatol."},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/ar4207","volume":"15","author":"MH Petri","year":"2013","unstructured":"Petri MH, Satoh M, Martin-Marquez BT, Vargas-Ramirez R, Jara LJ, Saavedra MA, et al. Implications in the difference of anti-Mi-2 and -p155\/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther. 2013;15:R48.","journal-title":"Arthritis Res Ther."},{"key":"573_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1172\/JCI108616","volume":"59","author":"JF Wolfe","year":"1977","unstructured":"Wolfe JF, Adelstein E, Sharp GC. Antinuclear antibody with distinct specificity for polymyositis. J Clin Invest. 1977;59:176\u20138.","journal-title":"J Clin Invest."},{"key":"573_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0074-7696(06)51005-8","volume":"251","author":"G Schilders","year":"2006","unstructured":"Schilders G, van Dijk E, Raijmakers R, Pruijn GJ. Cell and molecular biology of the exosome: how to make or break an RNA. Int Rev Cytol. 2006;251:159\u2013208.","journal-title":"Int Rev Cytol."},{"key":"573_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1084\/jem.173.4.941","volume":"173","author":"F Alderuccio","year":"1991","unstructured":"Alderuccio F, Chan EK, Tan EM. Molecular characterization of an autoantigen of PM-Scl in the polymyositis\/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J Exp Med. 1991;173:941\u201352.","journal-title":"J Exp Med."},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.176.4.973","volume":"176","author":"M Bluthner","year":"1992","unstructured":"Bluthner M, Bautz FA. Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD protein. J Exp Med. 1992;176:973\u201380.","journal-title":"J Exp Med."},{"key":"573_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1172\/JCI115895","volume":"90","author":"Q Ge","year":"1992","unstructured":"Ge Q, Frank MB, O'Brien C, Targoff IN. Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest. 1992;90:559\u201370.","journal-title":"J Clin Invest."},{"key":"573_CR12","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.4049\/jimmunol.137.12.3802","volume":"137","author":"G Reimer","year":"1986","unstructured":"Reimer G, Scheer U, Peters JM, Tan EM. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis\/scleroderma overlap syndromes. J Immunol. 1986;137:3802\u20138.","journal-title":"J Immunol."},{"key":"573_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00005792-199211000-00001","volume":"71","author":"C Marguerie","year":"1992","unstructured":"Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore). 1992;71:327\u201336.","journal-title":"Medicine (Baltimore)."},{"key":"573_CR14","first-page":"129","volume":"24","author":"F Vandergheynst","year":"2006","unstructured":"Vandergheynst F, Ocmant A, Sordet C, Humbel RL, Goetz J, Roufosse F, et al. Anti-pm\/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin Exp Rheumatol. 2006;24:129\u201333.","journal-title":"Clin Exp Rheumatol."},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","volume":"6","author":"M Mahler","year":"2007","unstructured":"Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev. 2007;6:432\u20137.","journal-title":"Autoimmun Rev."},{"key":"573_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.autrev.2008.12.001","volume":"8","author":"M Mahler","year":"2009","unstructured":"Mahler M, Fritzler MJ. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM\/Scl autoantibodies? Autoimmun Rev. 2009;8:373\u20138.","journal-title":"Autoimmun Rev."},{"key":"573_CR17","first-page":"1608","volume":"66","author":"J D\u2019Aoust","year":"2014","unstructured":"D\u2019Aoust J, Hudson M, Tatibouet S, Wick J. Canadian Scleroderma Research Group, Mahler M, et al. Clinical and serologic correlates of anti-PM\/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis. Rheumatol. 2014;66:1608\u201315.","journal-title":"Rheumatol."},{"key":"573_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/acr.22163","volume":"66","author":"K Kaji","year":"2014","unstructured":"Kaji K, Fertig N, Medsger Jr TA, Satoh T, Hoshino K, Hamaguchi Y, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken). 2014;66:575\u201384.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"573_CR19","doi-asserted-by":"publisher","first-page":"856815","DOI":"10.1155\/2013\/856815","volume":"2013","author":"Y Muro","year":"2013","unstructured":"Muro Y, Sugiura K, Akiyama M. A new ELISA for dermatomyositis autoantibodies: rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement. Clin Dev Immunol. 2013;2013:856815.","journal-title":"Clin Dev Immunol."},{"key":"573_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"573_CR21","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347.","journal-title":"Arthritis Rheum."},{"key":"573_CR22","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202\u20135.","journal-title":"J Rheumatol."},{"key":"573_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med."},{"key":"573_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1067\/mjd.2002.120621","volume":"46","author":"RD Sontheimer","year":"2002","unstructured":"Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626\u201336.","journal-title":"J Am Acad Dermatol."},{"key":"573_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271\u20137.","journal-title":"Arthritis Rheum."},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3109\/s10165-004-0338-x","volume":"14","author":"T Fujibayashi","year":"2004","unstructured":"Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sj\u00f6gren\u2019s syndrome (1999): availability and validity. Mod Rheumatol. 2004;14:425\u201334.","journal-title":"Mod Rheumatol."},{"key":"573_CR27","first-page":"615","volume":"17","author":"M Mosca","year":"1999","unstructured":"Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue disease (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999;17:615\u201320.","journal-title":"Clin Exp Rheumatol."},{"key":"573_CR28","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49:1726\u201333.","journal-title":"Rheumatology (Oxford)."},{"key":"573_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","volume":"49","author":"R Nakashima","year":"2010","unstructured":"Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49:433\u201340.","journal-title":"Rheumatology (Oxford)."},{"key":"573_CR30","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.20096","volume":"50","author":"A Watanabe","year":"2004","unstructured":"Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50:892\u2013900.","journal-title":"Arthritis Rheum."},{"key":"573_CR31","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar3495","volume":"13","author":"R Mierau","year":"2011","unstructured":"Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther. 2011;13:R172.","journal-title":"Arthritis Res Ther."},{"key":"573_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.1780370111","volume":"37","author":"M Kuwana","year":"1994","unstructured":"Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994;37:75\u201383.","journal-title":"Arthritis Rheum."},{"key":"573_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","volume":"158","author":"Y Hamaguchi","year":"2008","unstructured":"Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol. 2008;158:487\u201395.","journal-title":"Br J Dermatol."},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/1529-0131(199707)40:7<1257::AID-ART10>3.0.CO;2-R","volume":"40","author":"I Hausmanowa-Petrusewicz","year":"1997","unstructured":"Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:1257\u201366.","journal-title":"Arthritis Rheum."},{"key":"573_CR35","unstructured":"HLA laboratory. Haplotype\/ allele Freq. http:\/\/hla.or.jp\/haplo\/haplonavi.php?type=aril&lang=en."},{"key":"573_CR36","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/rheumatology\/kes033","volume":"51","author":"A Ishikawa","year":"2012","unstructured":"Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford). 2012;51:1181\u20137.","journal-title":"Rheumatology (Oxford)."},{"key":"573_CR37","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/rheumatology\/kes073","volume":"51","author":"Y Muro","year":"2012","unstructured":"Muro Y, Ishikawa A, Sugiura K, Akiyama M. Clinical features of anti-TIF1-\u03b1 antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-\u03b3 or anti-Mi-2 autoantibodies. Rheumatology (Oxford). 2012;51:1508\u201313.","journal-title":"Rheumatology (Oxford)."},{"key":"573_CR38","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1002\/art.38803","volume":"66","author":"Y Muro","year":"2014","unstructured":"Muro Y, Nakashima R, Hosono Y, Sugiura K, Mimori T, Akiyama M. Autoantibodies to DNA mismatch repair enzymes in polymyositis\/dermatomyositis and other autoimmune diseases: a possible marker of favorable prognosis. Arthritis Rheumatol. 2014;66:3457\u201362.","journal-title":"Arthritis Rheumatol."},{"key":"573_CR39","doi-asserted-by":"publisher","first-page":"R704","DOI":"10.1186\/ar1729","volume":"7","author":"M Mahler","year":"2005","unstructured":"Mahler M, Raijmakers R, D\u00e4hnrich C, Bl\u00fcthner M, Fritzler MJ. Clinical evaluation of autoantibodies to a novel PM\/Scl peptide antigen. Arthritis Res Ther. 2005;7:R704\u201313.","journal-title":"Arthritis Res Ther."},{"key":"573_CR40","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1136\/ard.2007.073981","volume":"67","author":"B Rozman","year":"2008","unstructured":"Rozman B, Cucnik S, Sodin-Semrl S, Czirj\u00e1k L, Varj\u00fa C, Distler O, et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case\u2013control study. Ann Rheum Dis. 2008;67:1282\u20136.","journal-title":"Ann Rheum Dis."},{"key":"573_CR41","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar2614","volume":"11","author":"K Hanke","year":"2009","unstructured":"Hanke K, Br\u00fcckner CS, D\u00e4hnrich C, Huscher D, Komorowski L, Meyer W, et al. Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther. 2009;11:R22.","journal-title":"Arthritis Res Ther."},{"key":"573_CR42","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.cca.2010.03.018","volume":"411","author":"L Maes","year":"2010","unstructured":"Maes L, Blockmans D, Verschueren P, Westhovens R, De Be\u00e9ck KO, Vermeersch P, et al. Anti-PM\/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma. Clin Chim Acta. 2010;411:965\u201371.","journal-title":"Clin Chim Acta."},{"key":"573_CR43","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/ar2276","volume":"9","author":"M Koenig","year":"2007","unstructured":"Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Sen\u00e9cal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007;9:R78.","journal-title":"Arthritis Res Ther."},{"key":"573_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2249.1990.tb05291.x","volume":"81","author":"C Gelpi","year":"1990","unstructured":"Gelpi C, Alguer\u00f3 A, Angeles Martinez M, Vidal S, Juarez C, Rodriguez-Sanchez JL. Identification of protein components reactive with anti-PM\/Scl autoantibodies. Clin Exp Immunol. 1990;81:59\u201364.","journal-title":"Clin Exp Immunol."},{"key":"573_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/ar389","volume":"4","author":"R Brouwer","year":"2002","unstructured":"Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van Engelen BG, Seelig HP, et al. Autoantibodies directed to novel components of the PM\/Scl complex, the human exosome. Arthritis Res. 2002;4:134\u20138.","journal-title":"Arthritis Res."},{"key":"573_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/art.20056","volume":"50","author":"R Raijmakers","year":"2004","unstructured":"Raijmakers R, Renz M, Wiemann C, Egberts WV, Seelig HP, van Venrooij WJ, et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis\/scleroderma overlap syndrome. Arthritis Rheum. 2004;50:565\u20139.","journal-title":"Arthritis Rheum."},{"key":"573_CR47","doi-asserted-by":"publisher","first-page":"30698","DOI":"10.1074\/jbc.M302488200","volume":"278","author":"R Raijmakers","year":"2003","unstructured":"Raijmakers R, Egberts WV, van Venrooij WJ, Pruijn GJ. The association of the human PM\/Scl-75 autoantigen with the exosome is dependent on a newly identified N terminus. J Biol Chem. 2003;278:30698\u2013704.","journal-title":"J Biol Chem."},{"key":"573_CR48","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.cca.2011.02.031","volume":"412","author":"TD Jaskowski","year":"2011","unstructured":"Jaskowski TD, Wilson A, Hill HR, Tebo AE. Diagnostic assays for anti-PM\/Scl IgG antibodies: heterogeneity in antibody response or lack of standardization? Clin Chim Acta. 2011;412:1100\u20135.","journal-title":"Clin Chim Acta."},{"key":"573_CR49","doi-asserted-by":"crossref","unstructured":"D\u2019Aoust J, Hudson M, Mahler M, Baron M, Fritzler MJ. Additional reasons to measure anti-PM1-Alpha antibodies in systemic sclerosis. Arthritis Rheumatol. 2014. doi: 10.1002\/art.38801.","DOI":"10.1002\/art.38801"},{"key":"573_CR50","first-page":"296","volume":"60","author":"R Guti\u00e9rrez-Ramos","year":"2008","unstructured":"Guti\u00e9rrez-Ramos R, Gonz Lez-D\u00edaz V, Pacheco-Tovar MG, L\u00f3pez-Luna A, Avalos-D\u00edaz E, Herrera-Esparza R. A dermatomyositis and scleroderma overlap syndrome with a remarkable high titer of anti-exosome antibodies. Reumatismo. 2008;60:296\u2013300.","journal-title":"Reumatismo."},{"key":"573_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaut.2014.01.019","volume":"48\u201349","author":"M Mosca","year":"2014","unstructured":"Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014;48\u201349:50\u20132.","journal-title":"J Autoimmun."},{"key":"573_CR52","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis."},{"key":"573_CR53","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/ard.2010.136929","volume":"70","author":"J Avouac","year":"2011","unstructured":"Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476\u201381.","journal-title":"Ann Rheum Dis."},{"key":"573_CR54","doi-asserted-by":"publisher","first-page":"390563","DOI":"10.1155\/2013\/390563","volume":"2013","author":"P Cordiali-Fei","year":"2013","unstructured":"Cordiali-Fei P, Mussi A, D\u2019Agosto G, Trento E, Bordignon V, Trincone S, et al. Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol. 2013;2013:390563.","journal-title":"Clin Dev Immunol."},{"key":"573_CR55","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3899\/jrheum.090652","volume":"37","author":"JC Lega","year":"2010","unstructured":"Lega JC, Cottin V, Fabien N, Thivolet-B\u00e9jui F, Cordier JF. Interstitial lung disease associated with anti-PM\/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol. 2010;37:1000\u20139.","journal-title":"J Rheumatol."},{"key":"573_CR56","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","volume":"162","author":"I Marie","year":"2010","unstructured":"Marie I, Lahaxe L, Benveniste O, Delavigne K, Adoue D, Mouthon L, et al. Long-term outcome of patients with polymyositis\/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol. 2010;162:337\u201344.","journal-title":"Br J Dermatol."},{"key":"573_CR57","first-page":"S12","volume":"30","author":"RW Koschik 2nd","year":"2012","unstructured":"Koschik 2nd RW, Fertig N, Lucas MR, Domsic RT, Medsger Jr TA. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol. 2012;30:S12\u20136.","journal-title":"Clin Exp Rheumatol."},{"key":"573_CR58","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","volume":"12","author":"S Mehra","year":"2013","unstructured":"Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340\u201354.","journal-title":"Autoimmun Rev."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0573-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0573-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0573-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0573-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:32:51Z","timestamp":1728923571000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0573-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0573-x","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,11]]},"assertion":[{"value":"18 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"57"}}